Previous 10 | Next 10 |
Gainers: Sunshine Biopharma ( SBFM ) +26% . InflaRx IFRX +14% . Talaris Therapeutics ( TALS ) +8% . Nutriband ( NTRB ) +7% . Biodesix ( BDSX ) +5% . Losers: Revelation Biosciences REVB -52% . Virax Biolabs VR...
InflaRx ( NASDAQ: IFRX ) stock rose ~13% on July 26 after its CEO Niels Riedemann said the company plans to submit a request for an emergency use authorization (EUA) of its COVID-19 drug vilobelimab in the U.S. by the end of Q3. The Germany company s...
Completed encouraging Type B meeting with US FDA Application for EUA planned to be submitted in Q3 2022 JENA, Germany, July 26, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting...
Gainers: MyMD Pharmaceuticals ( MYMD ) +23% . Clovis Oncology ( CLVS ) +22% . iRhythm Technologies ( IRTC ) +22% . Acer Therapeutics ( ACER ) +15% . Atreca ( BCEL ) +12% . Losers: RAPT Therapeutics ( RAPT ) -9% ...
The U.S. Food and Drug Administration (FDA) granted fast track designation to InflaRx's ( NASDAQ: IFRX ) vilobelimab to treat ulcerative pyoderma gangrenosum (PG). PG is a rare disorder which causes large, painful ulcers to develop on the skin, often on the legs. ...
US Food and Drug Administration awards Fast Track designation for the treatment of ulcerative pyoderma gangrenosum Fast track follows recently reported orphan drug designation by both US FDA and EMA JENA, Germany, July 06, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a ...
German biotech InflaRx N.V. ( NASDAQ: IFRX ) announced on Wednesday that the FDA agreed for a Type B meeting as the company seeks emergency use authorization for its COVID-19 therapy, vilobelimab The company has engaged the agency to discuss future regulatory path for vilo...
Orphan Drug Designation granted for treatment of pyoderma gangrenosum (PG) from US FDA and EMA Productive end-of-phase II meeting with FDA held for PG; dialogue ongoing related to Phase III program design Type B meeting scheduled with FDA; dialogue ongoing with EMA for development...
Gainers: Endo International plc (ENDP) +95%. Agile Therapeutics (AGRX) +66%. Kezar Life Sciences (KZR) +53%. Decibel Therapeutics (DBTX) +25%. Ceragon Networks (CRNT) +23%. InflaRx (IFRX) +20%. Sutro Biopharma (STRO) +19%. Tyra Biosciences (TYRA) +17%. Oasis Petroleum (OAS) +16%. Biotricity (...
The U.S. Food and Drug Administration (FDA) granted orphan drug designation to InflaRx's (NASDAQ:IFRX) vilobelimab to treat pyoderma gangrenosum (PG). PG is a rare disorder which causes large, painful ulcers to develop on the skin, often on the legs. The FDA grants orphan drug status to ...
News, Short Squeeze, Breakout and More Instantly...
JENA, Germany, June 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced today that GOHIBIC (vilobelimab) has been selected by the Biomedical Advanced Research and Development ...
Thought leaders in complement inhibition, chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) provide compelling new insights into the strong development rationales, potential differentiation and medical role of INF904 in initially targeted indications and inflammation & imm...
JENA, Germany, May 21, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced data presented at the American Thoracic Society (ATS) 2024 International Conference that is being held f...